Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 18/20 | 0.53 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13613613 | 0.87 | TRPV1 (0.57) | TRPV1OPRM1NPC1RAB9AALDH1A1 | |
| SCHEMBL13613610 | 0.87 | TRPV1 (0.53) | TRPV1OPRM1RAB9AALDH1A1PKM | |
| SCHEMBL13613651 | 0.87 | TRPV1 (0.53) | TRPV1OPRM1 | |
| SCHEMBL13613641 | 0.87 | TRPV1 (0.53) | TRPV1OPRM1 | |
| SCHEMBL13613632 | 0.86 | LMNA (0.54) | TRPV1OPRM1MEN1ALDH1A1GAA | |
| SCHEMBL13613667 | 0.86 | MEN1 (0.52) | TRPV1OPRM1MEN1ALDH1A1GAA | |
| SCHEMBL13613696 | 0.85 | TRPV1 (0.59) | TRPV1 | |
| SCHEMBL13613639 | 0.84 | TRPV1 (0.60) | TRPV1OPRM1 | |
| SCHEMBL13613606 | 0.84 | TRPV1 (0.59) | TRPV1OPRM1 | |
| SCHEMBL13613609 | 0.83 | TRPV1 (0.51) | TRPV1OPRM1NPC1RAB9AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7612113-B2 | Such as N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-(7-hydroxy-5,6,7,8-tetrahydro-1-naphthalenyl)urea; vanilloid receptor antagonists; for treatment of urge urinary incontinence, overactive bladder, chronic pain, neuropathic pain, postoperative pain, rheumatoid arthritic pain, neuralgia, neuropathies, COPD | XENTION LIMITED (GB) | 2009-11-03 | — | — | US | disclosed |
| US-7612113-B2 | Such as N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-(7-hydroxy-5,6,7,8-tetrahydro-1-naphthalenyl)urea; vanilloid receptor antagonists; for treatment of urge urinary incontinence, overactive bladder, chronic pain, neuropathic pain, postoperative pain, rheumatoid arthritic pain, neuralgia, neuropathies, COPD | XENTION LIMITED (GB) | 2009-11-03 | — | — | US | disclosed |